301665-60-1

Basic information

• Product Name: 1-Benzyl-4-broMo-piperidine
• Synonyms: 1-Benzyl-4-broMo-piperidine
• CAS NO: 301665-60-1
• Molecular Formula: C₁₂H₁₆BrN
• Molecular Weight: 254.16614
• Mol File: 301665-60-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 300.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.336±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 7.31±0.10(Predicted)
• CAS DataBase Reference: 1-Benzyl-4-broMo-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-broMo-piperidine(301665-60-1)
• EPA Substance Registry System: 1-Benzyl-4-broMo-piperidine(301665-60-1)

Safety Data

• Hazardous Substances Data: 301665-60-1(Hazardous Substances Data)

Usage

General Description

1-Benzyl-4-bromopiperidine is a chemical compound that belongs to the class of piperidine derivatives. It is also known by its IUPAC name, 1-benzyl-4-bromopiperidine. 1-Benzyl-4-broMo-piperidine is a brominated derivative of piperidine, a heterocyclic amine. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. 1-Benzyl-4-bromopiperidine has a variety of uses in the field of medicinal chemistry, particularly in the development of drugs targeting the central nervous system. It is also employed as a building block in the preparation of other nitrogen-containing compounds and can serve as a valuable tool for chemical research and development.

Upstream product

• 50-00-0 formaldehyd 
• 88381-98-0 N-(1-phenyl-3-butenyl)benzylamine 
• 76876-70-5 N-benzyl-4-(2-hydroxyethyl)piperidine 
• 54288-70-9 4-bromopiperidine hydrobromide 
• 100-52-7 benzaldehyde 
• 4727-72-4 1-benzyl-4-hydroxypiperidine 

Downstream Products

• 88796-11-6 (1-benzylpiperidin-4-yl)(phenyl)methanone 

Relevant articles and documents

Electroreductive Carbofunctionalization of Alkenes with Alkyl Bromides via a Radical-Polar Crossover Mechanism

Electrochemistry grants direct access to reactive intermediates (radicals and ions) in a controlled fashion toward selective organic transformations. This feature has been demonstrated in a variety of alkene functionalization reactions, most of which proceed via an anodic oxidation pathway. In this report, we further expand the scope of electrochemistry to the reductive functionalization of alkenes. In particular, the strategic choice of reagents and reaction conditions enabled a radical-polar crossover pathway wherein two distinct electrophiles can be added across an alkene in a highly chemo- and regioselective fashion. Specifically, we used this strategy in the intermolecular carboformylation, anti-Markovnikov hydroalkylation, and carbocarboxylation of alkenes - reactions with rare precedents in the literature - by means of the electroreductive generation of alkyl radical and carbanion intermediates. These reactions employ readily available starting materials (alkyl halides, alkenes, etc.) and simple, transition-metal-free conditions and display broad substrate scope and good tolerance of functional groups. A uniform protocol can be used to achieve all three transformations by simply altering the reaction medium. This development provides a new avenue for constructing Csp3-Csp3 bonds.

Narciclasine derivative, and preparation and application thereof in preparation of antitumor drugs

The invention provides a narciclasine derivative represented by the following structural formula I, wherein R1 is alkyl, cycloalkyl, benzyl or substituted benzyl, R2 is alkyl, cycloalkyl, benzyl or substituted benzyl, and n is an integer from 1 to 10. The narciclasine derivative is subjected to a tumor cell toxicity killing effect test, and results prove that the narciclasine derivative has strong toxicity killing effects on lung gland tumor cells, intestinal tumor cells, breast tumor cells, liver tumor cells, prostate tumor cells, melanoma tumor cells, endometrial tumor cells and neuroglia tumor cells, so the narciclasine derivative can be used for preparation of antitumor drugs. The invention provides a preparation method of the narciclasine derivative. The narciclasine derivative has a novel side-chain structure, shows excellent inhibitory activity on a variety of tumor cell strains, has drug efficacy better than that of narciclasine, allows toxic and side effects of the compound to be improved, provides new drugs for treatment of malignant tumors, and is of great clinical application value.